Clinical trial
A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients
NCT00046332 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00046332 |
|---|---|
| Title | A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients |
| Official title | A Phase II, Randomized, Placebo-controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Four Oral Doses of S-1360 Versus Placebo Over 10 Days in ART-naive HIV-1 Infected Adults. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | Shionogi Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | GW810781 |
| Enrollment | 100 |
| Start date | Jun 1, 2002 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | Sep 30, 2002 |
| Last update posted | Feb 21, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: